The US pharma industry saw a drop of 30.5% in overall deal activity during June 2019, when compared with the last 12-month average, according to GlobalData’s deals database.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all
  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

A total of 57 deals worth $14.44bn were announced in June 2019, compared to the 12-month average of 82 deals.

Venture financing was the leading category in the month in terms of volume with 41 deals which accounted for 71.9% of all deals.

In second place was M&A with 12 deals, followed by private equity with four transactions, respectively accounting for 21.05% and 7.02% of overall deal activity in the country’s pharma industry during the month.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In terms of value of deals, M&A was the leading deal category in the US pharma industry with total deals worth $13.36bn, while venture financing and private equity deals totalled $749.83m and $322.3m, respectively.

US pharma industry deals in June 2019: Top deals

The top five pharma industry deals accounted for 93.4% of the overall value during June 2019.

The combined value of the top five pharma industry deals stood at $13.48bn, against the overall value of $14.44bn recorded for the month. The top announced US pharma industry deal tracked by GlobalData in June 2019 was Pfizer’s $11.4bn acquisition of Array BioPharma.

In second place was the $1bn acquisition of Exonics Therapeutics by Vertex Pharmaceuticals and in third place was Merck &Inc’s $773m acquisition of Tilos Therapeutics.

The $200m private equity deal with Esperion Therapeutics by Oberland Capital Management and Upsher-Smith Laboratories’ asset transaction with Dr. Reddy’s Laboratories for $110.5m held fourth and fifth positions, respectively.

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.